期刊
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
卷 26, 期 5, 页码 358-367出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MNH.0000000000000343
关键词
chronic kidney disease; natriuresis; renal hemodynamic function; sodium-glucose cotransporter-2 inhibition
资金
- Banting & Best Diabetes CentreUniversity Health Network
- Eliot Phillipson Clinician Scientist Award in the Department of Medicine, University Health Network
- University of Toronto
- Canadian Society of Endocrinology and Metabolism
- Kidney Foundation of Canada
- Canadian Diabetes Association-KRESCENT
- CIHR
- Boehringer-Ingelheim
- Merck
- AstraZeneca
Purpose of review Our aim was to review the rationale for the role of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) as renoprotective therapy in patients with and without diabetes. Recent findings SGLT-2i are antihyperglycemic agents, approved for treating type 2 diabetes to reduce glycosylated hemoglobin, type A1c. Primary glucoregulatory effects occur through selective inhibition of SGLT-2 at the renal proximal tubule promoting glucosuria leading to blood glucose lowering. From a hemodynamic perspective, SGLT-2 inhibition is also associated with decreased glomerular hyperfiltration, an effect that is mediated through natriuresis and tubuloglomerular feedback. With renal injury and progressive nephron loss, diabetic kidney disease, and nondiabetic chronic kidney diseases share overlapping phenotypes exhibiting single nephron hyperfiltration, along with increased proteinuria. Importantly, the impact of SGLT-2 inhibition on renal and systemic hemodynamic function, including effects on lowering blood pressure, hyperfiltration, and plasma volume, are independent of blood glucose lowering and instead are because of natriuresis. Accordingly, large clinical trials with SGLT-2i investigating the potential use of SGLT-2i in patients without diabetes are now underway. Summary Based on prominent nonglycemic effects, the clinical use of SGLT-2i as renoprotective therapy may extend to nondiabetic chronic kidney diseases subtypes, which could help to address a large, unmet clinical need.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据